RAS Inhibitor Zoldonrasib Brings Clinical Benefit in Patients with G12D Mutated Non-Small Cell Advanced Lung Cancer

An interview with: Kathryn C Arbour MD, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York USA

And: Ryan B Corcoran MD PhD, Massachusetts General Cancer Center, Associate Professor of Medicine Harvard Medical School, Co-Chair, American Association for Cancer Research Clinical Trials Committee

CHICAGO, USA— The four per cent of patients with previously treated non-small cell lung cancer whose tumors harbor a KRAS G12D mutation may soon have an effective targeted treatment: currently an unmet need. Clinical benefit from the oral KRAS G12D inhibitor zoldonrasib is reported in findings presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting.

First author of the research Kathryn C Arbour MD, from Memorial Sloan Kettering Cancer Center in New York, told Audio Journal of Oncology correspondent Peter Goodwin how the drug’s ability to target both active and inactive conformations of the KRAS G12D oncogene could help overcome treatment resistance.

Ryan B Corcoran MD PhD, from the Massachusetts General Cancer Center and Harvard University, Co-Chair of the AACR Clinical Trials Committee, who was not involved with the research, adds his comments on the clinical implications for treating solid tumors harboring the RAS G12D mutation.

AACR 2025 Abstract Title:

“Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors”